Soleno Therapeutics

Soleno Therapeutics is a United States-based company headquartered in Redwood City, California. With a small team of 10 employees, Soleno focuses on researching and developing innovative medicines to address rare genetic disorders. The company's primary area of focus is Prader-Willi syndrome (PWS), a complex disorder with severe consequences. Soleno is developing DCCR, a Phase 3 oral tablet, as a potential treatment for PWS, aiming to manage the most debilitating symptoms associated with this condition. Soleno distinguishes itself through its commitment to pioneering therapies for rare diseases like PWS. Their dedication to research and development, specifically targeting a life-threatening disorder, sets them apart in the medical field. For more information about Soleno Therapeutics and its groundbreaking research, please visit their website at soleno.life.